1. Hong Kong Stocks

  2. •

    Non-energy minerals

  3. •

    Construction materials
Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd

HHKEX:1312
0.03
HKD
0.00
(0.00%)
145.30MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.18
0.18
0.09
0.13
0.27
0.38
0.17
0.18
0.14
0.16
0.15
0.16
0.16
- -
Basic EPS, GAAP
0.01
- -
-0.01
-0.01
- -
0.01
0.01
-0.05
- -
-0.01
-0.01
-0.01
-0.08
- -
Free Cash Flow per Basic Share
-0.02
-0.01
-0.02
-0.01
-0.03
- -
-0.01
- -
-0.01
-0.01
- -
0.01
0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.24
0.26
0.24
0.23
0.25
0.25
0.25
0.22
0.21
0.2
0.19
0.18
0.1
0.18
Tangible Book Value per Share
0.24
0.26
0.24
0.18
0.07
0.09
0.1
0.06
0.07
0.07
0.08
0.08
0.04
0.08
Basic Weighted Avg Shares
3,976
4,000
4,950
4,950
4,944
5,455
5,579
5,579
5,579
5,579
5,579
5,579
5,579
5,579
Sales/Revenue/Turnover
703
733
466
633
1,344
2,094
921
1,009
803
894
809
898
915
- -
Operating Margin (%)
4.62
5.02
-2.89
-6.04
5.66
8.64
4.4
3.46
-7.25
-10.87
-16.76
-5.28
-25.41
- -
Depreciation Expense
22
22
23
29
57
81
160
146
145
131
107
99
91
- -
Net Income, GAAP
33
17
-34
-37
-2
32
36
-267
-15
-42
-29
-76
-428
- -
Effective Tax Rate (%)
26.18
39.22
- -
- -
0.33
34.31
18.72
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
4.63
2.36
-7.35
-5.85
-0.13
1.55
3.92
-26.47
-1.87
-4.65
-3.56
-8.42
-46.77
- -
Working Capital
790
1,396
1,150
844
511
381
419
150
78
185
204
115
-91
115
LT Debt
66
185
- -
163
177
1
368
467
422
368
228
147
75
147
Total Equity
1,210
1,714
1,609
1,643
1,849
1,909
1,921
1,354
1,338
1,156
1,062
962
476
962
Return on Invested Capital (%)
1.75
1.19
- -
- -
1.68
3.39
1.53
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
1.77
0.9
- -
- -
-0.66
0.87
0.9
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
4.28
1.67
-2.75
-3.18
-0.15
2.48
2.57
-20.35
-1.25
-3.62
-2.67
-7.42
-55.86
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
106
106
151
LT Borrowings
13
- -
- -
LT Finance Leases
215
179
147
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,589
5,589
5,589
Market Capitalization
201
190
145

Working Capital

HKD

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
588
595
557
Cash, Cash Equivalents & STI
88
79
91
Accounts Receivable, Net
107
144
109
Inventories
98
91
86
Total Current Liabilities
384
405
442
Payables & Accruals
- -
- -
- -
ST Debt
106
106
151
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.38%
-16.57%
-50.47%
Free Cash Flow
2.45%
-37.33%
59.1%
Net Income, GAAP
-213.58%
135.89%
466.41%
Sales/Revenue/Turnover
15.18%
-1.15%
1.92%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
809
2024
- -
- -
898
2025
- -
- -
915

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.01
2025
- -
- -
-0.08

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Feifei Wang
Full Time Employees
636
Sector
Non-energy minerals
Industry
Construction materials
Address
Sun Hung Kai Centre Hong Kong Hong Kong
IPO Date
Jan 18, 2012
Website
kontafarma.com.hk
Similar Companies
Ambuja Cements Limited (NSE:AMBUJACEM)
ACC Limited (NSE:ACC)
Grasim Industries Ltd. (NSE:GRASIM)
UltraTech Cement Limited (NSE:ULTRACEMCO)
OYAK Cimento Fabrikalari A.S. (BIST:OYAKC)
Cimsa Cimento Sanayi ve Ticaret A.S. (BIST:CIMSA)
Business
Kontafarma China Holdings Limited (1312.HK) is an investment holding company principally engaged in the manufacture and sale of prescription drugs and the operation of fitness centers. Incorporated in the Cayman Islands in 2011 and listed on the Hong Kong Stock Exchange in 2012, the company is headquartered in Wan Chai, Hong Kong, and operates primarily through its subsidiaries in Mainland China, with additional reach in Singapore, Taiwan, and internationally; it is a subsidiary of China Health Management Investment Limited. The Pharmaceutical Business segment manufactures and sells chemical drugs, active pharmaceutical ingredients (API), API intermediates, prescribed traditional Chinese medicines, injection powders, tablets, capsules, ointments, synthetic drugs, preparations, biochemical drugs, and laboratory-related products, adhering to GMP standards in its plants and including chloroquine phosphate for pneumonia treatment; the Fitness Business segment operates fitness and yoga centers, provides consultation services for fitness and health activities, and manages franchise operations for royalty income. In a key development, a subsidiary entered into a contract in 2025 valued at RMB33.7 million for constructing a Beijing R&D complex to bolster research and development capabilities, with the transaction approved at an adjourned extraordinary general meeting; the company also reported interim results for the six months ended June 30, 2025, reflecting revenue of HKD453 million and a net loss amid fitness segment challenges; it previously acquired Tongfang Pharmaceutical Group Co., Ltd. (formerly Beijing Ziguang Pharmaceutical Co., Ltd.) in 2016 and changed its name from Tongfang Kontafarma Holdings Limited in September 2022.